Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Y-Mabs Therapeutics Inc (YMAB)

Y-Mabs Therapeutics Inc (YMAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Y-Mabs Therapeutics Inc 230 Park Avenue Suite 3350 NEW YORK NY 10169 USA

www.ymabs.com P: 646-885-8505

Description:

Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company's product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA.

Key Statistics

Overview:

Market Capitalization, $K 752,422
Enterprise Value, $K 673,782
Shares Outstanding, K 43,873
Annual Sales, $ 84,820 K
Annual Net Income, $ -21,430 K
Last Quarter Sales, $ 23,360 K
Last Quarter Net Income, $ -990 K
EBIT, $ -25,670 K
EBITDA, $ -24,930 K
60-Month Beta 0.78
% of Insider Shareholders 21.50%
% of Institutional Shareholders 70.85%
Float, K 34,440
% Float 78.50%
Short Volume Ratio 0.29

Growth:

1-Year Return 148.77%
3-Year Return -49.85%
5-Year Return -23.78%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 67.33%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.02 on 02/29/24
Latest Earnings Date 05/07/24 [AMC]
Earnings Per Share ttm -0.49
EPS Growth vs. Prev Qtr 88.89%
EPS Growth vs. Prev Year -166.67%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

YMAB Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -20.72%
Return-on-Assets % -16.28%
Profit Margin % -25.27%
Debt/Equity 0.00
Price/Sales 8.92
Price/Cash Flow N/A
Price/Book 7.45
Book Value/Share 2.32
Interest Coverage -0.54
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar